glp 1 agonist gila monster Why Useless Knowledge Can Be So Useful Science's 2023 Breakthrough: GLP-1R Agonists

Clin Med Insights: Endocrinol Diabetes

A true breakthrough: The eye-opening potential of GLP-1 agonists to treat heart, kidney disease in addition to obesity Science , a popular journal published by the American Association for the Advancement of Science (AAAS), has announced that ongoing research into the benefits of GLP-1 agonists such as semaglutide is its 2023 Breakthrough of the Year

doi:10.1158/1078-0432.CCR-21-0715 136

Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism

Conclusion Prolonged fasting periods regarding solid meal components, point-of-care ultrasound examination for retained gastric content, and the use of prokinetic medications like erythromycin may prove helpful and represent an important area needing further study to increase patient safety for those treated with GLP-1 RAs